Top Analyst Ratings: May 7th, 2025

Latest Analyst Ratings: Monday June 16th, 2025

Top Analyst Ratings

McDonald’s (MCD)-UBS Securities

  • Rating: Buy

  • New Price Target: $350 USD (from $345)

  • Action: Target Up

  • Details: UBS raised its price target for McDonald’s from $345 to $350 while maintaining a “Buy” rating. The upward revision reflects continued strength in same-store sales, driven by successful menu innovations and increased digital engagement. UBS highlights the company’s resilience in a challenging economic environment and its strategic focus on delivery and loyalty programs as key growth drivers.


Tesla (TSLA) – Morgan Stanley

  • New Price Target: $410 USD

  • Action: Target Update

  • Details: Morgan Stanley reaffirmed its “Buy” rating for Tesla, increasing the price target to $410. The positive outlook is based on robust demand for Tesla’s electric vehicles (EVs), especially with strong pre-orders for the new Cybertruck. Morgan Stanley also noted Tesla’s advancements in battery technology and autonomous driving as significant competitive advantages.


Advanced Micro Devices (AMD) – Bank of America

  • Rating: Buy

  • New Price Target: $120 USD

  • Action: Upgrade

  • Details: Bank of America upgraded AMD to “Buy” from a “Neutral” rating, setting a new price target of $120. The upgrade reflects confidence in AMD’s competitive positioning in the semiconductor space, particularly with its latest lineup of AI-centric processors and increasing presence in data centers. The firm also noted that AMD’s focus on AI workloads positions it favorably against rivals like Intel and NVIDIA.


Biogen Inc. (BIIB) – Mizuho Securities

  • Rating: Buy

  • New Price Target: $169 USD

  • Action: Target Update

  • Details: Mizuho Securities reiterated its “Buy” rating for Biogen, updating the price target to $169. The adjustment is linked to positive developments in Biogen’s Alzheimer’s drug portfolio, including promising trial data for a treatment targeting early-stage symptoms. Mizuho analysts see potential for significant revenue growth as the drug advances through regulatory stages.


Alimentation Couche-Tard (ATD:CA) – National Bank

  • Rating: Outperform

  • New Price Target: 81 CAD

  • Action: Target Down

  • Details: National Bank lowered the price target for ATD from a higher figure to 81 CAD while maintaining an “Outperform” rating. The revision is attributed to temporary cost headwinds, particularly related to fuel price volatility impacting margins. Despite the target decrease, the long-term outlook remains optimistic due to the company’s strategic acquisitions and robust cash flow generation.

Ad